



PRESCRIPTION FORM

| | |
|----------------|---|
| PATIENT | PATIENT NAME: _____ DOB: _____ PHONE: _____ DX/ICD10: _____ |
| | ADDRESS: _____ ALLERGIES: _____ |

| | |
|---------------------|--|
| PRESCRIPTION | <p>1. Compound Semaglutide 2mg-1ml in SubMagna™ HMW #15ml</p> <p>i. *INITIAL DOSE* Place 0.25ml under tongue for 90 seconds minimum - swallow once daily, increase to 0.5ml on second week, do not eat for 30 minutes (<i>Recommended for new patients</i>)</p> <p>ii. *STANDARD DOSE* Place 0.5ml under tongue for 90 seconds minimum - swallow once daily, do not eat for 30 minutes (<i>Recommended for patients near or at target weight to maintain</i>)</p> <p>2. Other _____ (Medication, Directions, Quantity, Day Supply, Refills)</p> <p>One does NOT have to use this order form for prescribing and could simply E-Prescribe through normal conventional systems should that be desired. In many ways, that can be easier for the prescriber. Call the pharmacy to discuss this further if you need any help adding the compound into your EMR system. Mycelium Pharmacy Ft. Lauderdale, FL 33334 Phone: 954-890-1150 Fax: 954-393-0670 Email: info@myceliumpharmacy.com (NCPDP: 1052416)</p> <p>Refills: (Number of refills indicated here refers to all medications prescribed above) 1 Year 5 3 1 Zero</p> <p>*Please note if a daily dose is missed the medication has a 7 day half life and no 'double dose' would be required the next day of administration.</p> <p><input type="checkbox"/> 3. Optional add on- Magna-Multi Daily Support Dietary Supplement (during weight loss)-30 Capsules</p> |
|---------------------|--|

| | | | |
|-------------------|-------------------------------|----------------|---|
| PRESCRIBER | PRESCRIBER'S SIGNATURE: _____ | | DATE _____ |
| | FACILITY | CONTACT | |
| | ADDRESS | CITY/STATE/ZIP | |
| | EMAIL | PHONE | FAX |
| | PRESCRIBER | NPI | DEA |
| | | | <p>PRESCRIBER'S NOTES</p> <div style="border: 1px solid black; height: 150px; width: 100%;"></div> <p style="text-align: right;">ID: _____</p> <p style="text-align: right; font-size: small;">Updated 04_30_2021</p> |

Confidentiality Notice: This facsimile transmission is intended only for the address shown above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. Any review, discrimination or use of this transmission or any of its contents by person other than the addressee is strictly prohibited. If you received this fax in error, please shred the facsimile documents immediately. Drug Disclaimer: Our pharmacy works with practitioners to provide them with compounding options for their patients' medication challenges. No claims are made as to the safety and efficacy of these compounds. CA indicates a commercially available medication. CMPD indicates a medication compounded by the pharmacy. No compounded medication is reviewed by the FDA for safety and efficacy. SUSP refers Suspension. Oint refers Ointment, TAB refers Tablet, CAP refers Capsule, DISP refers to Dispense. CRM refers to Cream. AM refers Apply Affected Area. Compounded sublingual Semaglutide is being compounded using crushed RYBELSUS® tablets to obtain the Semaglutide. FDA does not review compounded medication for safety or efficacy. RYBELSUS® is a registered trademark of Novo Nordisk A/S.

Version FC.20.3